Jeremy Bender Sells 7,873 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) CEO Jeremy Bender sold 7,873 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $126,597.84. Following the completion of the transaction, the chief executive officer now directly owns 654,728 shares of the company’s stock, valued at $10,528,026.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jeremy Bender also recently made the following trade(s):

  • On Friday, May 3rd, Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.85, for a total value of $163,398.90.
  • On Wednesday, May 1st, Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.88, for a total transaction of $1,252,511.88.

Day One Biopharmaceuticals Trading Up 0.9 %

Shares of NASDAQ DAWN traded up $0.14 during midday trading on Friday, reaching $16.17. The company’s stock had a trading volume of 421,575 shares, compared to its average volume of 1,732,325. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -6.44 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a one year low of $9.67 and a one year high of $18.07. The company has a 50 day moving average price of $15.44 and a 200 day moving average price of $14.45.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth about $29,000. Quintet Private Bank Europe S.A. grew its position in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank increased its stake in Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares during the period. Exchange Traded Concepts LLC lifted its position in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after buying an additional 2,554 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 352.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after buying an additional 7,841 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on DAWN. JPMorgan Chase & Co. boosted their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. HC Wainwright decreased their price target on Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Read Our Latest Research Report on DAWN

About Day One Biopharmaceuticals

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

See Also

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.